Schizophrenia
Diagnosis
One of:
Hallucinations
Delusions
Thought Disorder
Or two of:
Catatonia
Negative Symptoms
Consistent Change in Personal Behaviour
Earlier Diagnosis Improves Outcome
Prodromal Diagnosis
Bonn Scale (BSABS)
Diminished Affectivity
Disturbed Contact
Cognitive, Personal or Self-Disorder
Perplexity and Cenethesias
Prognosis
Reduced Life Expectancy
Suicide in males
CVD in females
Brain Imaging
PF4015: PET Scans
PET images contain more or less intense colour to provide information about chemical activity within certain organs and tissues.
Treatment
First Generation Antipsychotics
Chemistry: Chlorpromazine developed from phenothiazine compounds
Side Effects
Mainly associated with movement disorders - decreased nigrostriatal dopamine activity
Hyperprolactinemia, sedation, weight gain. muscarinic and alpha adrenergic - decreased tuberoinfundibular dopamine activity
Second Generation Antipsychotics
Pharmaceutics: Risperdal Consta® Depot IM Injection
Reduced incidence of EPSE's
Third Generation Antipyschotic?
Aripirazole
Partial D2 agonist
5HT2A antagonist
Partial 5HT1A agonist
Reduced incidence of hyperprolactinemia and EPSE's
CBT or Family Interventions
Future Treatment
Novel targets - drugs targeting glutamatergic, cholinegeric and nicotinic receptors and signalling proteins such as PDE and AKT. Theoretically rationale but no proof.
Target risk genes - DISC-1, neuregulin and RGS proteins
Natalizumab
No treatment to alleviate negative and cognitive symptoms
Pathophysiology
Dopamine Hypothesis
D2 Receptors
D1 Receptors
Dihydrexidine is a selective D1 agonist
that has shown positive results in clinical trials where there was significant increase in bilateral prefrontal cortical perfusion after infusion of the drug
Serotonin Hypothesis
5HT1A receptors have been shown to be increased in the frontal cortex, hippocampus, and thalamus in schizophrenia - causing decreased dopaminergic activity
Glutamate Hypothesis
Etiology
Stress-Vulnerability
Neurodevelopmental
Slight defects of the head, hair, eyes, mouth, feet and hands
Ventricular enlargement
Genetics
Not due to a single gene mutation
About 33% chance of both identical
twins developing the disease, compared to 7%
chance in non-identical twins
Combination of environmental factors and genetics
Transmitter Abnormality
Risk Factors:
Prenatal and Perinatal Complications
Social Deprivation
Urban Living
Ethnicity
Cannabis Use
Re-hospitilisations, psychosocial functioning, alcohol abuse and relapse more common among cannabis abusers
Immigrants
Symptoms
Cognitive
Decreased processing speed
Decreased episodic memory
Poor executive function
Positive
Hallucinations
Delusions
Confused thoughts/Difficulty concerntrating
Disorganised or unpredictable behaviour
Negative
Social withdrawal
Deterioration in appearance and hygeine
Anhedonia
Loss of motivation
Misconception
Pharmacoeconomic Effects
Cost of €460.6 million in Ireland in 2006
Medication
Psychiatric Therapy
Co-morbidities and hospital admissions
High incidence of physical and social disability
Patients require care services
on daily basis - family member, friend or care worker
Majority of patients are unable to work and require social welfare